Cantor Fitzgerald Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-Buy
Editas Medicine (NASDAQ:EDIT – Get Free Report) was upgraded by Cantor Fitzgerald from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports. Separately, HC Wainwright initiated coverage on Editas Medicine in a research report on Monday. They set a “buy” rating and a $3.00 price objective for the company. […]
Editas Medicine (NASDAQ:EDIT – Get Free Report) was upgraded by Cantor Fitzgerald from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports. Separately, HC Wainwright initiated coverage on Editas Medicine in a research report on Monday. They set a “buy” rating and a $3.00 price objective for the company. […]
